Drug intelligence / Profile preview

escitalopram

Development stage
Approved
Lead developer
Lundbeck
Modality
Small Molecules
Administration
Oral
01

Overview

Escitalopram is a selective serotonin reuptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is primarily used to treat major depressive disorder (MDD) in adults and adolescents aged 12 years and older, as well as generalized anxiety disorder (GAD) in adults. Escitalopram works by increasing levels of serotonin in the brain through potent inhibition of the serotonin transporter (SERT), which prevents reuptake of serotonin into presynaptic neurons. This action helps restore serotonergic function, alleviating symptoms of depression and anxiety. Escitalopram exhibits high selectivity for SERT compared to other monoamine transporters, contributing to its favorable side effect profile relative to less-selective SSRIs. Additionally, it binds allosterically to SERT, potentially enhancing its efficacy and speed of onset compared with other SSRIs. The drug was originally developed by Lundbeck.

Brand names
Lexapro
Other names
S-citalopram
02

Targets

SERT allosteric site (Serotonin transporter allosteric site)

Beyond the preview

Go deeper on escitalopram.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on escitalopram.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call